title: Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
abstract: The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features. A total of 443 in-patients were treated with 300 mg fluvoxamine (n = 307) or 20-40 mg paroxetine (n = 136) for 6 wk. The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for Depression (HAMD). Allele variants were determined in each subject using a PCR-based technique. We observed a marginal association between 5-HT-2A variants and antidepressant response while MAOA genotypes were not associated. Possible stratification factors, such as sex, diagnosis, presence of psychotic features, HAMD scores at baseline, pindolol augmentation and SSRIs plasma levels did not significantly influence the observed results. The investigated MAOA and 5-HT-2A gene variants, therefore, do not seem to play a major role in SSRI antidepressant activity.
authors.affiliation: Department of Psychiatry, Vita-Salute University, Raffaele del Monte Tabor, Milan, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Cusin
authors.forename: Alessandro
authors.initials: A
authors.lastname: Serretti
authors.forename: Raffaella
authors.initials: R
authors.lastname: Zanardi
authors.forename: Enrico
authors.initials: E
authors.lastname: Lattuada
authors.forename: David
authors.initials: D
authors.lastname: Rossini
authors.forename: Roberta
authors.initials: R
authors.lastname: Lilli
authors.forename: Cristina
authors.initials: C
authors.lastname: Lorenzi
authors.forename: Enrico
authors.initials: E
authors.lastname: Smeraldi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use; D005838:Genotype; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000235:genetics*; D017374:Paroxetine / Q000627:therapeutic use; D010869:Pindolol / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics / Q000502:physiology*; D011569:Psychiatric Status Rating Scales; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012727:Sex Characteristics
chemical_list: D000319:Adrenergic beta-Antagonists; D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D016666:Fluvoxamine; D008094:Lithium; D008995:Monoamine Oxidase; D017374:Paroxetine; D010869:Pindolol; D044402:Receptor, Serotonin, 5-HT2A; D017367:Selective Serotonin Reuptake Inhibitors